Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Achieve Life Sciences, Inc. announced promising results from its ORCA-3 clinical trial of cytisinicline for smoking cessation, published in JAMA Internal Medicine. This Phase 3 study involved 792 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results